1. 연사 : 조중명 박사 - 크리스탈지노믹스(주)
2. 연제 : Accelerating Drug Discovery based on Structural Chemoproteomics
3. 일시 : 2004년 3월 30일 (화) 오후 4:00
4. 장소 : 의과학센터 원격강의실
※ 문의 : 서연수 교수님 (2637)
※ Abstract
Currently, while there are too many drug targets available from bioinformatics, functional genomics, proteomics and chemical genomics, we are poor in novel drug leads in pharmarceutical business. We need new technologies to speed up drug discovery process. The Structural Proteomics and ChemoProteomics based on 3-D structures of disease target proteins are emerging as promising technologies for rapid drug discovery, because they enable researchers to design drug leads efficiently.
With the integrated technology to obtain soluble forms of disease related proteins (Soluble Protein Solution: SPSTM), the 3-D structures of target proteins are determined efficiently. The novel drug leads based on the 3-D structures can be generated rapidly using the technology named Structural ChemoProteomics (SCPTM). These technologies include proprietary in silico screening technique, NMR technique, and the method of generating highly focused chemical libraries based on the folding dictionaries of active sites of target protein such as kinases, phosphatases, and phosphodiesterases. The developmental drug candidates are synthesized by the integrated platform technology (Structure-based Drug Factory: SDFTM) to productively optimize novel drug leads to candidates using the 3-D structure informations of the complexes of target proteins and leads. These technologies include x-ray crystallography, proprietary Leadinformatics and smart chemistry with combi-chem, parallel and microwave synthsis.
As more genomic and proteomics informations emerge requiring functional annotation and as more structures are solved, these platform technologies of generating novel drugs based on the 3-D structures of target proteins will become one of the most efficient and productive ways for drug discovery today.
2. 연제 : Accelerating Drug Discovery based on Structural Chemoproteomics
3. 일시 : 2004년 3월 30일 (화) 오후 4:00
4. 장소 : 의과학센터 원격강의실
※ 문의 : 서연수 교수님 (2637)
※ Abstract
Currently, while there are too many drug targets available from bioinformatics, functional genomics, proteomics and chemical genomics, we are poor in novel drug leads in pharmarceutical business. We need new technologies to speed up drug discovery process. The Structural Proteomics and ChemoProteomics based on 3-D structures of disease target proteins are emerging as promising technologies for rapid drug discovery, because they enable researchers to design drug leads efficiently.
With the integrated technology to obtain soluble forms of disease related proteins (Soluble Protein Solution: SPSTM), the 3-D structures of target proteins are determined efficiently. The novel drug leads based on the 3-D structures can be generated rapidly using the technology named Structural ChemoProteomics (SCPTM). These technologies include proprietary in silico screening technique, NMR technique, and the method of generating highly focused chemical libraries based on the folding dictionaries of active sites of target protein such as kinases, phosphatases, and phosphodiesterases. The developmental drug candidates are synthesized by the integrated platform technology (Structure-based Drug Factory: SDFTM) to productively optimize novel drug leads to candidates using the 3-D structure informations of the complexes of target proteins and leads. These technologies include x-ray crystallography, proprietary Leadinformatics and smart chemistry with combi-chem, parallel and microwave synthsis.
As more genomic and proteomics informations emerge requiring functional annotation and as more structures are solved, these platform technologies of generating novel drugs based on the 3-D structures of target proteins will become one of the most efficient and productive ways for drug discovery today.
